Indivior / Sagent Pharma Raleigh NC

Indivior retained PharmaBioSource, Inc. as its exclusive consultant to identify sterile injectable drug product manufacturing facilities in the U.S. as potential acquisition targets. Indivior was seeking to acquire an existing facility to manufacture SUBLOCADE®, its opioid use disorder (OUD) treatment. PharmaBioSource was engaged to identify and profile pharma manufacturing facility acquisition opportunities and assist Indivior in narrowing down the opportunities that best met its manufacturing capabilities and capacity requirements. PharmaBioSource then approached senior management representatives at the prioritized targets to inquire if an acquisition scenario was possible.

PharmaBioSource prepared a landscape of all of the sterile injectable drug product manufacturing facilities in the U.S. to provide a list of potential acquisition opportunities for Indivior to consider. Over 100 targets were identified, and each target was profiled, including location, facility size, manufacturing capabilities and capacities, regulatory status, and workforce availability. Partnering with Indivior, each target was reviewed to determine which facilities best met Indivior’s manufacturing capabilities and capacity requirements. We drew on our technical expertise and extensive contacts within the life sciences industry to approach the prioritized targets to engage them in discussions toward potential acquisition opportunities. Ultimately, the Sagent Pharma manufacturing facility in Raleigh, NC, was selected as the best acquisition opportunity for Indivior.

Services provided by the PharmaBioSource team:

• Target identification and profiling
• Prioritized acquisition targets that best met Indivior’s needs
• Market engagement
• Managed confidentiality agreements
• Attended site visits and meetings with Indivior and Sagent management teams
• Supported Indivior’s due diligence
• Data room review
• Contract document review
• Deal structure and negotiations
• Closing support

PharmaBioSource managed the entire target identification and acquisition process resulting in Indivior’s successful purchase of the Sagent sterile injectable drug product manufacturing facility in Raleigh, NC. This acquisition allowed Indivior to avoid a more than $250M investment in a new manufacturing facility and reduced its time to market by more than three years.